Aptevo Therapeutics Inc

NASDAQ:APVO   3:59:51 PM EDT
3.60
+0.07 (+1.98%)
Products, Regulatory

Aptevo Therapeutics Announces New Preliminary Remission Data On Four Additional Patients Enrolled In On-Going Apvo436 Dose Expansion Phase 1B Trial

Published: 06/09/2022 12:23 GMT
Aptevo Therapeutics Inc (APVO) - Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going Apvo436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia.
Aptevo Therapeutics Inc- Cohort 1 Combination Therapy Arm Shows 36% Remission Rate Among Response-evaluable Patients Treated to Date.
Aptevo Therapeutics Inc- Cohort 3 Monotherapy Patient Achieved Bone Marrow Complete Remission.
Aptevo Therapeutics Inc- Myelodysplastic Syndrome Patient Enrolled in Dose Escalation Trial Remains Stable and on Apvo436 After 18 Months of Treatment.